Uncertainties in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

被引：50

作者：

Hansen, Karen E. ^{[1
]}

Wilson, H. Alexander ^{[2
]}

Zapalowski, Carol ^{[3
]}

Fink, Howard A. ^{[4
]}

Minisola, Salvatore ^{[5
]}

Adler, Robert A. ^{[6
,7
,8
]}

机构：

[1] Univ Wisconsin, Dept Med, Madison, WI USA

[2] Bone Hlth Ctr, Newport News, VA USA

[3] Denver Ctr Bone Hlth, Denver, CO USA

[4] Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Minneapolis, MN USA

[5] Univ Roma La Sapienza, Rome, Italy

[6] McGuire Vet Affairs Med Ctr, Endocrinol & Metab Sect, Richmond, VA USA

[7] Virginia Commonwealth Univ, Dept Med, Sch Med, Richmond, VA 23298 USA

[8] Virginia Commonwealth Univ, Dept Epidemiol, Sch Med, Richmond, VA USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2011年 / 26卷 / 09期

关键词：

CORTICOSTEROID-INDUCED OSTEOPOROSIS; INDUCED BONE LOSS; VERTEBRAL FRACTURE; DOUBLE-BLIND; APPROPRIATENESS CRITERIA; AMERICAN-SOCIETY; ZOLEDRONIC ACID; TASK-FORCE; RISEDRONATE; ALENDRONATE;

D O I：

10.1002/jbmr.362

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Much knowledge has accrued since the 2001 American College of Rheumatology (ACR) guidelines were published to assist clinicians in the prevention and treatment of glucocorticoid-induced osteoporosis (GIO). Therefore, the ACR undertook a comprehensive effort to review the literature and update the GIO guidelines [Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515-1526]. Herein, we review the new guidelines for JBMR readers, highlighting the changes introduced by the 2010 publication. We discuss several patient scenarios for which the new treatment guidelines do not apply, or for which our committee interprets existing literature differently and suggests an alternative approach. (C) 2011 American Society for Bone and Mineral Research.

引用

页码：1989 / 1996

页数：8

共 51 条

[1]

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].

Adachi, JD ;

Bensen, WG ;

Brown, J ;

Hanley, D ;

Hodsman, A ;

Josse, R ;

Kendler, DL ;

Lentle, B ;

Olszynski, W ;

SteMarie, LG ;

Tenenhouse, A ;

Chines, AA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387

[2]

Adachi JD, 2001, ARTHRITIS RHEUM-US, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO

[3]

2-W

[4]

Adler RA, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P1135

[5]

Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496

[6]

Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis [J].

Carbonare, LD ;

Arlot, ME ;

Chavassieux, PM ;

Roux, JP ;

Portero, NR ;

Meunier, PJ .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (01) :97-103

[7]

Chappard D, 1996, J BONE MINER RES, V11, P676

[8]

Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO

[9]

2-K

[10]

Management of glucocorticoid-induced osteoporosis [J].

Compston, Juliet .

NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (02) :82-88

← 1 2 3 4 5 6 →